Cowen Sees 'Mixed' Response in PTC Therapeutics (PTCT) After Royal Pharma's Risdiplam Deal
Tweet Send to a Friend
Cowen analyst Joseph Thome reiterated a Market Perform rating and $50.00 price target on PTC Therapeutics (NASDAQ: PTCT) after Royalty ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
